Genetic determinants of CYP2A6 activity across racial/ ethnic groups with different risks of lung cancer and effect on their smoking intensity

Carcinogenesis

Volumn 37, Issue 3, 2015, Pages 269-279

  Park, Sungshim L ^a   Tiirikainen, Maarit I ^b   Patel, Yesha M ^a   Wilkens, Lynne R ^b   Stram, Daniel O ^a   Marchand, Loic Le ^b   Murphy, Sharon E ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYP2A6 PROTEIN, HUMAN; NICOTINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN AMERICAN; BODY MASS; CAUCASIAN; COHORT ANALYSIS; COPY NUMBER VARIATION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METABOLISM; NATIVE HAWAIIAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SMOKING; URINALYSIS; ADVERSE EFFECTS; DNA MICROARRAY; ETHNIC GROUP; ETHNOLOGY; GENETIC VARIATION; GENETICS; LIQUID CHROMATOGRAPHY; LUNG NEOPLASMS; MASS SPECTROMETRY; MIDDLE AGED;

ADULT; AGED; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; CYTOCHROME P-450 CYP2A6; ETHNIC GROUPS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NICOTINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS; SMOKING;

EID: 84959880188     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw012     Document Type: Article

References (39)

1. Torre, L.A. et al. (2015) Global cancer statistics, 2012. CA Cancer J. Clin., 65, 87-108.
2. Haiman, C.A. et al. (2006) Ethnic and racial differences in the smokingrelated risk of lung cancer. N. Engl. J. Med., 354, 333-342.
3. Hukkanen, J. et al. (2005) Metabolism and disposition kinetics of nicotine. Pharmacol. Rev., 57, 79-115.
4. Scherer, G. et al. (2007) Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul. Toxicol. Pharmacol., 47, 171-183.
5. Wang J. et al. (2011) Is 24h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure? Biomarkers, 16, 144-154.
6. Benowitz, N.L. et al. (2006) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther., 80, 457-467.
7. Murphy, S.E. et al. (2014) Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. Carcinogenesis, 35, 2526-2533.
8. Zhang, X. et al. (2002) Effects of whole deletion of CYP2A6 on nicotine metabolism in humans. Drug Chem. Toxicol., 25, 203-213.
9. Nakajima, M. et al. (2000) Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther., 67, 57-69.
10. Mwenifumbo, J.C. et al. (2007) Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics, 8, 1385-1402.
11. Malaiyandi, V. et al. (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry, 11, 400-409.
12. Minematsu, N. et al. (2006) Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur. Respir. J., 27, 289-292.
13. Wassenaar, C.A. et al. (2011) Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst., 103, 1342-1346.
14. Derby, K.S. et al. (2008) Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol. Biomark. Prev., 17, 3526-3535.
15. Miyamoto, M. et al. (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun., 261, 658-660.
16. Ariyoshi, N. et al. (2002) Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomark. Prev., 11, 890-894.
17. Wang, L. et al. (2013) Association of CYP2A6*4 with susceptibility of lung cancer: a meta-analysis. PLoS One, 8, e59556.
18. Kumasaka, N. et al. (2012) Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. PLoS One, 7, e44507.
19. Wassenaar, C.A. et al. (2015) CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers- findings from two independent populations. Carcinogenesis, 36, 99-103.
20. Xu, C. et al. (2002) An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290, 318-324.
21. Bloom, J. et al. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet. Genomics, 21, 403-416.
22. Haberl, M. et al. (2005) Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics, 15, 609-624.
23. Ho, M.K. et al. (2008) A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet. Genomics, 18, 67-75.
24. Park, S.L. et al. (2015) Variation in levels of the lung carcinogen NNAL and its glucuronides in the urine of cigarette smokers from five ethnic groups with differing risks for lung cancer. Cancer Epidemiol. Biomark. Prev., 24, 561-569.
25. Kolonel, L.N. et al. (2000) A multiethnic cohort in Hawaii and Los Angeles:baseline characteristics. Am. J. Epidemiol., 151, 346-357.
26. Carmella, S.G. et al. (2013) High throughput liquid and gas chromatography- tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem. Res. Toxicol., 26, 1209-1217.
27. Patel, Y.M. et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol. Biomark. Prev., 24, 119-127.
28. Strasser, A.A. et al. (2011) Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol. Biomark. Prev., 20, 234-238.
29. Stephens, M. et al. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
30. Bloom, A.J. et al. (2012) Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum. Mol. Genet., 21, 3050-3062.
31. Mwenifumbo, J.C. et al. (2005) Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet. Genomics, 15, 189-192.
32. Raunio, H. et al. (2012) CYP2A6: genetics, structure, regulation, and function. Drug Metabol. Drug Interact., 27, 73-88.
33. Mwenifumbo, J.C. et al. (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat., 29, 679-688.
34. Piliguian, M. et al. (2014) Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenet. Genomics, 24, 118-128.
35. Kandel, D.B. et al. (2007) Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am. J. Epidemiol., 165, 901-910.
36. Bloom, A.J. et al. (2013) A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. Pharmacogenet. Genomics, 23, 107-116.
37. Liu, T. et al. (2013) Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. Environ. Mol. Mutagen., 54, 133-140.
38. Yuan, J.M. et al. (2015) Downregulation of cell cycle-related proteins in ovarian cancer line and cell cycle arrest induced by microRNA. Int. J. Clin. Exp. Med., 8, 18476-18481.
39. Wakai, K. et al.; JACC Study Group. (2005) Updated information on risk factors for lung cancer: findings from the JACC Study. J. Epidemiol., 15 (suppl. 20), S134-S139.